Analyst Profile

Followed by 53 followers
.
Yanan Zhu

Yanan Zhu

Wells Fargo
Wall Street Analyst
#7,451 out of 8,141 Wall Street Analysts
#22,401 out of 24,284 experts

Success Rate

31%
11 out of 35 transactions made a profit

Average Return

-13.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Yanan Zhu's trades since 2020 and holding each position for 1 Year would result in 31.43% of your transactions generating a profit, with an average return of -13.7% per rating.

Stock Rating Distribution

56Ratings
67.86% Buy
32.14% Hold
0.00% Sell
Distribution of Yanan Zhu's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Momenta Pharmaceuticals
(MNTA)
Rating:Buy
Date:Nov 06, 2019 - Aug 19, 2020
Return:+233.00%
The most profitable rating made by Yanan Zhu

Yanan Zhu's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
MNTA
Momenta Pharma
Aug 19, 2020
Hold
Downgraded
3Ratings
100%
+139.55%
Argenx Se
Feb 02, 2021
Hold
Reiterated
$326.00
(-12.79% Downside)
4Ratings
0.00%
Morphic Holding
Mar 01, 2021
Buy
Reiterated
$103.00
(274.27% Upside)
1Ratings
0%
-53.20%
Voyager Therapeutics
Oct 06, 2021
Hold
Reiterated
$5.00
(-9.26% Downside)
1Ratings
0.00%
Avrobio
Jan 04, 2022
Buy
Reiterated
$8.00
(790.87% Upside)
2Ratings
0%
-78.50%
Avidity Biosciences
Jan 07, 2022
Buy
Reiterated
5Ratings
0%
-29.08%
Intellia Therapeutics
Jan 07, 2022
Buy
Reiterated
1Ratings
0%
-52.80%
Editas Medicine
Jan 07, 2022
Buy
Reiterated
$61.00
(508.18% Upside)
5Ratings
0%
-64.15%
CCXI
ChemoCentryx
Jan 07, 2022
Buy
Reiterated
$62.00
(19.25% Upside)
3Ratings
67%
+60.37%
Crispr Therapeutics AG
Jan 07, 2022
Hold
Reiterated
$105.00
(90.94% Upside)
1Ratings
0.00%
List of latest recommendations made by Yanan Zhu. Click to expand and see Yanan Zhu's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >